BEIGENE (06160.HK) announced that according to US GAAP, the company expects to achieve positive operating income for the full ...

BeiGene (ONC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. BeiGene stock just hit that mark, ...

StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock. Several other ...

Analyst Jill Wu of CMB International Securities maintained a Buy rating on BeiGene (ONC – Research Report), boosting the price target to ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Dealmakers at BeiGene, Brii Biosciences and Ideaya Biosciences had a busy end to the year, sharing news of agreements for antibody-drug conjugates (ADCs) and other assets in the final few days of ...

David Li, an analyst from Bank of America Securities, maintained the Hold rating on BeiGene (ONC – Research Report). The associated price ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

Stock analysts at StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Get Free Report) in a report released on Saturday. The brokerage set a “hold” rating on the stock. A number of ...

Tevimbra is under clinical development by BeiGene and currently in Phase I for Urethral Cancer. According to GlobalData, Phase I drugs for Urethral Cancer does not have sufficient historical data to ...